Medijski sadržaj
- Tweetovi
- Tweetovi i odgovori
- Medijski sadržaj, trenutna stranica.
-
Gilead preparing a trial in China of remdesivir to treat 2019-nCoV: https://biocentury.com/article/304364 . At least 9 trials of #2019-nCoV therapies are underway. https://biocentury.com/article/304364 All BioCentury coverage of the outbreak is in front of the paywall at https://biocentury.com/coronavirus .
@V2019Npic.twitter.com/eKrq2JK5Sq
-
Data will be critical to curtailing the #2019-nCoV outbreak. It looks like China is starting trials to gather data about treatments: http://biocentury.com/article/304364 . List of 9 trials below. Also Gilead preparing a trial in China of remdesivir to treat 2019-nCoV: https://biocentury.com/article/304364 .pic.twitter.com/uOCDalHRmA
-
Gilead preparing a trial in China of remdesivir to treat 2019-nCoV: https://www.biocentury.com/article/304364 . Meanwhile, at least 9 trials of #2019-nCoV therapies are underway. https://www.biocentury.com/article/304364 All BioCentury coverage of the outbreak is in front of the paywall at https://www.biocentury.com/coronavirus .pic.twitter.com/MR9Bhpq0Pn
-
Another thing to consider re #2019-nCoV: China has become integrated into global drug development. China in general, and Wuhan in particular, are the sites of many drug trials. These aren't likely to priorities in a public health emergency. https://www.biocentury.com/article/304351 pic.twitter.com/W6ngfc3hZv
-
HHS declares #2019-nCoV a public health emergency. Separate declarations will be needed to allow FDA to issue Emergency Use Authorizations (EUAs), e.g., for use of unapproved diagnostics. https://www.biocentury.com/article/304341 pic.twitter.com/J1Ue0n6l4p
-
A dozen #2019-nCoV vaccine development programs have been announced, five efforts to discover and develop therapeutic antibodies.
@V2019N https://www.biocentury.com/bc-extra/clinical-news/2020-01-30/industry-and-academic-centers-are-rushing-create-new-vaccines-and- …pic.twitter.com/GWcSDuBcZg
-
One way to look at the price of biosimilars is to consider whether they are discounted from the launch price of the original product. For example, two recent Pfizer biosimilars launched at about double the original products' launch prices. https://www.biocentury.com/bc-extra/company-news/2020-01-24/pfizer-seeking-dent-market-share-trio-discounted-biosimilars …pic.twitter.com/QEGFYGeitm
-
At least 8 #2019-nCoV vaccines under development using a variety of technologies. List below. In addition at least three groups are working on mAbs: Regeneron, Vir, and NIH’s NIAID. mAbs might be ready faster and provide both prophylaxis and treatment. https://www.biocentury.com/biocentury/product-development/2020-01-24/coronavirus-outbreak-creating-testbed-new-vaccine-and- …pic.twitter.com/1xM3lTbeqz
-
At least 8 #2019-nCoV vaccines under development using a variety of technologies. List below. In addition at least three groups are working on mAbs: Regeneron, Vir, and NIH’s NIAID. mAbs might be ready faster and provide both prophylaxis and treatment. https://www.biocentury.com/biocentury/product-development/2020-01-24/coronavirus-outbreak-creating-testbed-new-vaccine-and- …pic.twitter.com/ZZn4WIdRvQ
-
Publication of the gene sequence of the Wuhan coronavirus has sparked a race to develop vaccines and drugs. The first could be monoclonal antibodies that are both treatment and prophylaxis. https://www.biocentury.com/biocentury/product-development/2020-01-24/coronavirus-outbreak-creating-testbed-new-vaccine-and- …pic.twitter.com/KbyHRdh7GV
-
Racing to create a vaccine to against the Wuhan virus: NIH partnering w Moderna on an mRNA vaccine. Baylor testing a SARS vaccine candidate. Novavax working on one. BUT public health steps hopefully will contain the virus before the vaccines. https://www.biocentury.com/bc-extra/preclinical-news/2020-01-21/moderna-novavax-among-biotechs-working-wuhan-virus-vaccine- …
#nCoV2019pic.twitter.com/Kor61XtTpS
-
BSC sponsored a U.S. tour for an astrologer who predicted bad luck for Hitler and good omens for FDR. Described in "Bureau of Spies"pic.twitter.com/k7yHQuFrHA
-
Is immuno-oncology a bubble? "The science is real; the results are potentially transformational. The question is whether the current level of investment is justified." https://www.biocentury.com/biocentury/finance/2020-01-13/guest-commentary-immuno-oncology-investments-taking-over-cancer-rd- …pic.twitter.com/hh9COO8xPh
-
Sobering Washington Post story outlines consequences of Trump administration fetal tissue ban: https://www.washingtonpost.com/health/trump-restrictions-on-fetal-tissue-research-unsettle-key-studies-and-scientists/2020/01/13/b4efa312-f1e1-11e9-8693-f487e46784aa_story.html … In June I challenged the biopharma industry to speak out. So far... crickets. https://www.biocentury.com/biocentury/politics-policy-law/2019-06-14/editor%E2%80%99s-commentary-biopharma-companies-should-speak- …pic.twitter.com/pUs0LiXxyt
-
Some CFIUS news: in a win for biotech, final FIRRMA regulation narrows definition of "genetic data" that can trigger review of a foreign investment. https://www.biocentury.com/bc-extra/politics-policy/2020-01-13/treasury-narrows-definition-genetic-data-cfius-reviews …pic.twitter.com/bGE4HgnlsM
-
The Supreme Court announced Monday that it would not hear any of 3 cases that could have helped clarify what, if any, diagnostics can be patented. Over the last decade the Supreme Court Dx IP decisions have befuddled lower courts and stifled investment. https://www.biocentury.com/bc-extra/politics-policy/2020-01-13/supreme-court-declines-clean-its-ip-mess …pic.twitter.com/dSC2sGW5Qf
-
Academic institutions lag far behind industry in complying with clinical trial reporting requirements. https://www.biocentury.com/bc-extra/politics-policy/2020-01-13/academic-sponsors-lag-industry-reporting-clinical-trial-results …pic.twitter.com/AwiemEQbJ3
-
Over 200 biopharma leaders endorse commitment to patients and the public https://www.biocentury.com/biocentury/politics-policy-law/2020-01-08/why-over-200-biopharma-leaders-have-signed-new-commitment- …pic.twitter.com/44FfYIDGMC
-
Biopharma leaders hope a public commitment will start to turn around the industry's reputation. https://www.biocentury.com/biocentury/politics-policy-law/2020-01-08/why-over-200-biopharma-leaders-have-signed-new-commitment- …pic.twitter.com/T1kpHTazEO
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.